amylin vs glp-1 Amylin: From Mode of Action to Future Clinical Potential in Diabetes and Obesity Amycretin — a novel obesity

These medications not only promote significant weight loss, which reduces airway obstruction but may also improve neuromuscular control of breathing

As the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) expands, so too does our knowledge of just what all these medications can do

While prevalence remains uncertain, symptoms have been reported in up to 30% of postsurgical patients

An expected surge in generic GLP-1s is anticipated to reshape not only pharmaceutical pricing and access but also the global MedTech ecosystem supporting drug delivery.

To help people figure out who qualifies, whats involved and what to expect for first-time GLP-1 users, a pair of weight management specialists at MUSC Health sat down for this Q&A.

At present, GLP-1RAs have become highly effective treatments for managing type 2 diabetes mellitus and obesity